Project Grant R01HL171240
Award Date
9/1/24
Completion Date
6/30/29
Dollars Obligated
$604K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,788 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), with a project period from September 15, 2024 to June 30, 2026. The goal of this project is to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $260,586 to the University of Wisconsin-Madison over a 5-year period starting September 1, 2024. The objective is to develop and optimize a novel positron emission tomography (PET) probe that can monitor extracellular matrix deposition and disease activity in idiopathic pulmonary fibrosis (IPF), a fatal lung disease characterized by...
This Project Grant award of $5,715,866 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop novel, transformative therapies that substantially reduce the burden of morbidity and mortality from progressive pulmonary fibrosis (PF). The multi-year program, which began in September 2024, focuses on investigating the transcriptomic, genetic, epigenetic, metabolic, and environmental signatures that contribute to the initiation and early...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $171,858 to Brigham & Women's Hospital Inc. (a subsidiary of Partners Healthcare System) to conduct research on "Computed Tomography for Early Detection and Phenotyping of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease with Implications for Treatment." The research aims to: 1) identify and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,989 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop, train, and test deep generative models using computed tomography (CT) images to predict lung injury progression and treatment responses in patients with acute respiratory distress syndrome (ARDS). The goal is to leverage artificial intelligence and image...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $812,189 to Brigham & Women's Hospital Inc. for a research project titled "Clinical CT Imaging for Screening and Subtyping of Pulmonary Hypertension in COPD". The project aims to leverage CT imaging data from several NIH-funded cohorts, including PVDOMICS, COPDGENE, and CARDIA, to develop non-invasive methods for diagnosing...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $145,642 to Georgia Tech Research Corporation to engineer 3D pulmonary microtissue models to explore the role of fibroblast senescence in the development and progression of idiopathic pulmonary fibrosis (IPF). The project aims to: 1) develop an in vitro pulmonary microtissue model to assess differences in contractility, stiffness, cell...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI, CFDA 93.837 - Cardiovascular Diseases Research) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) totaling $827,753 aims to develop new computational methods for systems genetic analysis of the rare polygenic disorder idiopathic pulmonary fibrosis (IPF). The project will pursue three key strategies: (1) pleiotropy-informed SNP association tests, (2) polygenic risk scores to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $183,388 to Dr. Jennifer Wang at the University of Michigan to conduct research on defining and characterizing the clinical syndrome of combined pulmonary fibrosis and emphysema (CPFE) using quantitative CT imaging techniques. The primary objectives are to: 1) Define CPFE through quantitative imaging methodologies, and 2)...